Bifidobacterium longum subsp. infantis 35624
Bifidobacterium longum subsp. infantis 35624 is a clinically studied probiotic strain that produces short-chain fatty acids and antimicrobial compounds. It modulates gut microbiota composition and enhances intestinal barrier function through competitive exclusion of pathogenic bacteria.
Origin & History
Bifidobacterium longum subsp. infantis 35624 is a probiotic strain isolated from the human gastrointestinal tract, particularly prevalent in infants.
Historical & Cultural Context
Bifidobacterium longum has been used in traditional fermented foods and probiotics, valued for its health-promoting properties across various cultures.
Health Benefits
- Supports digestive health by promoting a balanced gut microbiome, increasing beneficial bacteria by up to 40% in studies. This balance aids in reducing gastrointestinal discomfort. - Enhances immune function by modulating immune responses, leading to a 25% increase in protective antibodies. This helps the body defend against pathogens more effectively. - Reduces inflammation by decreasing pro-inflammatory cytokines, which can lower inflammation markers by 15%. This is essential for preventing chronic inflammatory diseases. - Alleviates symptoms of irritable bowel syndrome (IBS) by normalizing bowel movements and reducing bloating. This leads to improved quality of life for IBS sufferers. - Supports infant gut health by colonizing the intestines with beneficial bacteria, crucial for developing a strong immune system. This is particularly important in early life stages. - Enhances nutrient absorption by improving gut barrier function, which increases the uptake of essential vitamins and minerals. This supports overall health and vitality. - Promotes mental well-being by influencing the gut-brain axis, potentially reducing anxiety and depression symptoms. A healthy gut is linked to a healthier mind.
How It Works
This strain produces butyrate and acetate short-chain fatty acids that strengthen intestinal tight junctions and reduce inflammation via NF-κB pathway inhibition. It synthesizes antimicrobial peptides and competes with pathogens for adhesion sites on intestinal epithelial cells. The strain also stimulates secretory IgA production and modulates dendritic cell responses to enhance mucosal immunity.
Scientific Research
Bifidobacterium longum subsp. infantis 35624 has been extensively studied, with research supporting its role in improving digestive health and reducing IBS symptoms.
Clinical Summary
Randomized controlled trials with 120-362 participants have demonstrated this strain's efficacy for irritable bowel syndrome and digestive health. Studies show 40% increases in beneficial bacteria populations and 25% improvements in protective antibody levels after 4-8 weeks of supplementation. The strain has been specifically tested in doses of 1×10^8 to 1×10^10 CFU daily. Evidence quality is moderate with most studies being small-scale but well-controlled.
Nutritional Profile
- Contains live probiotic bacteria. - Available in capsule or powder form. - Free from artificial colors and preservatives.
Preparation & Dosage
Recommended dosage is 1 to 10 billion CFU per day. Consult a healthcare provider before use.
Synergy & Pairings
Lactobacillus rhamnosus, Omega-3 fatty acids, Fiber
Safety & Interactions
Bifidobacterium longum subsp. infantis 35624 is generally well-tolerated with mild gastrointestinal symptoms like bloating occurring in less than 5% of users during initial weeks. No significant drug interactions have been reported, though it may theoretically affect antibiotic efficacy if taken concurrently. Immunocompromised individuals should consult healthcare providers before use due to rare risk of bacteremia. Safety during pregnancy and breastfeeding has not been specifically studied for this strain.